BioSpace News Archive

Atea Pharmaceuticals, Inc. today announced that it will present analyses confirming data previously reported relating to the AT-527 COVID-19 clinical trial program at the ISIRV-WHO virtual conference COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment, to be held on October 19 – 21, 2021.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Thursday, November 4, 2021 at 8:30 a.m. ET .

Exicure , Inc. today announced presentations in the following scientific conferences during the month of October: 17th International Congress on Neuronal Ceroid Lipofuscinosis (NCLs)

Rapid Therapeutics Science Laboratories (OTC: RTSL) (“Rapid Therapeutic’’ or the “Company”), a growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announces today that its shareholder update conference call scheduled for today following the close of market has been postponed.

Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates

MINDCURE invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, announced the appointment of Doug Schenkel as Chief Financial Officer.

StageZero Life Sciences, Ltd. announced today that patients in Virginia and the Washington, D.C. metropolitan area (D.C., Md., Va.) can now directly access Aristotle™, the company’s multi-cancer blood test, via its Richmond, Va. laboratory.

Recursion today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for the investigation of REC-2282 for treatment of patients with NF2-mutated meningiomas, including neurofibromatosis type-2 disease-related meningiomas.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced results from a retrospective analysis of the pooled results of three randomized trilaciclib studies showing that patients with extensive-stage small-cell lung cancer who received the drug prior to each chemotherapy treatment had significantly lower use of supportive care therapies for chemotherapy-induced myelosuppression than patients who received placebo.